Lucence and laboratory diagnostics distributor Omnigen have entered a new partnership to bring amplicon-based liquid biopsy tests for cancer to Turkey.
Under the deal terms, Omnigen will be responsible for distributing Lucence’s liquid biopsy tests to Turkish hospitals and clinicians.
The company will distribute Lucence’s LiquidHALLMARK next-generation sequencing (NGS) assay.
The assay targets circulating DNA and RNA to profile the unique cancer of a patient.
It profiles ctDNA mutations in 80 genes, fusions in ten genes, and somatic variants and also analyses 27 ctRNA targets for emerging fusions.
The test works by targeting genes that are commonly related to 15 cancers, which include breast, colon, and lung cancer.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Lucence stated that the LiquidHALLMARK test would be performed in its CAP-accredited, CLIA-certified labs.
Lucence founding CEO and medical director Dr Min-Han Tan said: “We are extremely eager to embark on this partnership with Omnigen who is a leading provider of oncology solutions in Turkey at the bridge of Europe and Asia.
“Our mission is to serve patients worldwide with quick, reliable and affordable answers for cancer care.”
According to the company, Turkey saw more than 230,000 new cancer cases in 2020.
Lucence noted that its LiquidHALLMARK test had been validated in breast, lung, and colorectal cancers, which are the most common types in the region.
Omnigen general manager and CEO Ali Kilinc said: “NGS tests constitute a large part of the cancer diagnostics market in Turkey.
“These tests shed light on alternative treatments for patients who do not respond to standard treatment.”